Jayachandran Mamatha, Geevarughese Nikku M, Palatty Princy L, Baliga-Rao Manjeshwar Poonam, Sacheendran Dhanya, Baliga Manjeshwar S
Department of Pharmacology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ernakulam, IND.
Department of Hand Surgery, Kasturba Medical College Manipal, Manipal Academy of Higher Education, Manipal, IND.
Cureus. 2024 Oct 22;16(10):e72092. doi: 10.7759/cureus.72092. eCollection 2024 Oct.
Treating widely prevalent bone illnesses such as back and neck pain, osteoarthritis, rheumatoid arthritis, gout, and osteoporosis with pharmacological medication can be excessively costly for both the individual and their family. This study aimed to conduct a cost minimization analysis by comparing the prices of Jan Aushadhi (JA) medications with the most expensive and least expensive branded alternatives available in India.
The prices of the most costly, least costly branded, and JA medicines were acquired from the relevant websites. The cost difference, cost ratio, and percentage of cost variation were determined based on the guidelines outlined in the cost minimization analysis research.
A total of 67 drugs/combinations used to treat various chronic bone ailments were analyzed. With regard to analgesic/anti-inflammatory drugs, the most expensive brand of diclofenac sodium + serratiopeptidase (50mg + 10mg) tablet was 32.5 times more expensive than the cheapest and 10.5 times more costly than the JA brand. Also, the paracetamol 325mg + tramadol 37.5mg combination of the branded tablets was more expensive than JA. Branded cyclosporine was 2.3 times more expensive than JA among immunosuppressants in the disease-modifying antirheumatic drugs (DMARD) group. The most expensive immunomodulator, leflunomide, costs four times more than JA. Hydrocortisone injection, an adjuvant, costs 10.8 times more than the cheapest and 2.1 times more than JA. IL-1 inhibitor + nutraceutical combination costs 4.8 times more than the costliest JA brand. Zoledronic acid was 16.1 and 6.8 times more expensive than the cheapest branded and JA drugs. Xanthine oxidase inhibitor febuxostat, used to treat gout, costs 5.2 and 3.3 times more than JA and the cheapest brands.
This cost minimization study, the first to the best of our knowledge in the field of chronic musculoskeletal ailments, indicates the usefulness of JA drugs in reducing the patient's financial costs for most drugs.
使用药物治疗诸如背痛、颈痛、骨关节炎、类风湿性关节炎、痛风和骨质疏松症等广泛流行的骨骼疾病，对个人及其家庭来说成本可能过高。本研究旨在通过比较印度贾恩·奥沙迪（JA）药物与最昂贵和最便宜的品牌替代药物的价格，进行成本最小化分析。
从相关网站获取最昂贵、最便宜的品牌药物和JA药物的价格。根据成本最小化分析研究中概述的指南，确定成本差异、成本比和成本变化百分比。
共分析了67种用于治疗各种慢性骨骼疾病的药物/组合。在镇痛/抗炎药物方面，双氯芬酸钠+沙雷肽酶（50毫克+10毫克）片剂最昂贵的品牌比最便宜的品牌贵32.5倍，比JA品牌贵10.5倍。此外，品牌片剂中对乙酰氨基酚325毫克+曲马多37.5毫克的组合比JA药物更贵。在改善病情抗风湿药物（DMARD）组的免疫抑制剂中，品牌环孢素比JA药物贵2.3倍。最昂贵的免疫调节剂来氟米特的成本是JA药物的四倍。辅助药物氢化可的松注射液比最便宜的品牌贵10.8倍，比JA药物贵2.1倍。白细胞介素-1抑制剂+营养补充剂组合的成本是最昂贵的JA品牌的4.8倍。唑来膦酸比最便宜的品牌药物和JA药物分别贵16.1倍和6.8倍。用于治疗痛风的黄嘌呤氧化酶抑制剂非布司他比JA药物和最便宜的品牌分别贵5.2倍和3.3倍。
据我们所知，这项成本最小化研究是慢性肌肉骨骼疾病领域的首个此类研究，表明JA药物在降低大多数药物患者的经济成本方面是有用的。
